Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 See also 2 References

Danuglipron

●فارسی Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Danuglipron
Clinical data

Other names	PF-06882961
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-[[4-[6-[(4-Cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
CAS Number	2230198-02-2
PubChem CID	134611040
UNII	DN9IUI24GP
ChEMBL	ChEMBL4518483
CompTox Dashboard (EPA)	DTXSID601101457
Chemical and physical data
Formula	C₃₁H₃₀FN₅O₄
Molar mass	555.610 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F
InChI InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1 Key:HYBAKUMPISVZQP-DEOSSOPVSA-N

Danuglipron is a small-molecule GLP-1 agonist developed by Pfizer^[1] that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicate that it reduced weight^[2] and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.^[3]^[4]

References[edit]

^ Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, et al. (June 2022). "A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor". Journal of Medicinal Chemistry. 65 (12): 8208–8226. doi:10.1021/acs.jmedchem.1c01856. PMC 9234956. PMID 35647711.

^ Medical Weight Loss

^ Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ (May 2023). "Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial". JAMA Network Open. 6 (5): e2314493. doi:10.1001/jamanetworkopen.2023.14493. PMC 10203889. PMID 37213102.

^ Constantino, Annika Kim (2023-12-02). "Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops". CNBC. Retrieved 2023-12-03.

Oral diabetes medication, insulins and insulin analogs, and other drugs used in diabetes (A10)

Insulins/insulin analogs

fast-acting	Insulin aspart Insulin glulisine Insulin lispro
short-acting	Regular insulin^#
long-acting	Insulin detemir^# Insulin glargine^# (+lixisenatide) NPH insulin Lente insulin^‡ Ultralente insulin^‡
ultra-long-acting	Insulin degludec^# (+insulin aspart, +liraglutide) Insulin icodec^† (+semaglutide)
inhalable	Exubera^‡ Afrezza

^#WHO-EM

^‡Withdrawn from market

Clinical trials:

^†Phase III
^§Never to phase III

Non-insulins

Insulin sensitizers

Biguanides	Buformin^‡ Metformin^# Phenformin^‡
TZDs/"glitazones" (PPAR)	Ciglitazone^§ Darglitazone^§ Englitazone^§ Lobeglitazone Netoglitazone^§ Pioglitazone Rivoglitazone^† Rosiglitazone Troglitazone^‡
Dual PPAR agonists	Aleglitazar^† Muraglitazar^§ Saroglitazar Tesaglitazar^§
Amylin analogs and DACRAs	Cagrilintide^§ Pramlintide

Secretagogues

K⁺_ATP

Sulfonylureas

2nd generation: Glibenclamide (glyburide)
Glibornuride
Glicaramide
Gliclazide^#
Glimepiride
Glipizide
Gliquidone
Glisoxepide
Glyclopyramide

Meglitinides/"glinides"

GLP-1 receptor agonists

GLP1 poly-agonist peptides

Mazdutide (GLP-1/GCGR)
Retatrutide^§ (GLP-1/GIP/GCGR)
Tirzepatide (GLP-1/GIP)

DPP-4 inhibitors/"gliptins"

Other

Aldose reductase inhibitors	Epalrestat Fidarestat^§ Ranirestat^† Tolrestat^‡ Zenarestat^§
Alpha-glucosidase inhibitors	Acarbose Miglitol Voglibose
SGLT2 inhibitors/"gliflozins"	Canagliflozin Dapagliflozin Empagliflozin^# Ertugliflozin Ipragliflozin Luseogliflozin Remogliflozin^§ Sergliflozin^§ Sotagliflozin Tofogliflozin^† Velagliflozin
Other	Benfluorex^‡ Bromocriptine Imeglimin

Combinations

^#WHO-EM

^‡Withdrawn from market

Clinical trials:

^†Phase III
^§Never to phase III

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Danuglipron&oldid=1229167539" Categories: ●Experimental drugs ●GLP-1 receptor agonists ●Experimental diabetes drugs ●Nitriles ●Fluoroarenes ●Pyridines ●Ethers ●Piperidines ●Oxetanes ●Benzimidazoles ●Carboxylic acids ●Gastrointestinal system drug stubs Hidden categories: ●Articles with short description ●Short description matches Wikidata ●Drugs with non-standard legal status ●Chemical pages without ChemSpiderID ●Chemical pages without DrugBank identifier ●Articles without KEGG source ●Drugs missing an ATC code ●Articles containing unverified chemical infoboxes ●All stub articles ●This page was last edited on 15 June 2024, at 07:27 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view